Author

Ashraf Badros

Professor of Medicine; University of Maryland - Cited by 17,471 - Director of Multiple Myeloma Service

Biography

Dr. Badros has extensive clinical experience in Bone Marrow Transplantation with special interest in multiple myeloma. He was involved in the initial trails of thalidomide and has conducted many clinical trials for treatment of relapsed and refractory multiple myeloma. Dr. Badros research has focused on evaluation of immunological approaches to eradicate residual myeloma cells in the high-risk setting following autologous stem cell transplantation using natural killer (NK) and interleukin -2 (IL-2) activated cells and non-myeloablative allogeneic donor grafts.
Title
Cited by
Year
Corneal epithelial findings in patients with multiple myeloma treated with antibody–drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study
AV Farooq, S Degli Esposti, R Popat, P Thulasi, S Lonial, AK Nooka, ...Ophthalmology and Therapy 9, 8-911, 2020202
89
2020
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ...Cancer 127 (22), 4198-4212, 2021202
80
2021
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
L Rosiñol, M Beksac, E Zamagni, NWCJ Van de Donk, KC Anderson, ...British journal of haematology 194 (3), 496-507, 2021202
56
2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
C Fernández de Larrea, R Kyle, L Rosiñol, B Paiva, M Engelhardt, ...Blood cancer journal 11 (12), 192, 2021202
56
2021
Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes
NG Holtzman, H Xie, S Bentzen, V Kesari, A Bukhari, F El Chaer, F Lutfi, ...Neuro-oncology 23 (1), 112-121, 2021202
45
2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
S Lonial, AK Nooka, P Thulasi, AZ Badros, BH Jeng, NS Callander, ...Blood Cancer Journal 11 (5), 103, 2021202
32
2021
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
S Lonial, R Popat, C Hulin, S Jagannath, A Oriol, PG Richardson, T Facon, ...The Lancet Haematology 9 (11), e822-e832, 2022202
19
2022
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
HW Auner, M Gavriatopoulou, S Delimpasi, M Simonova, I Spicka, L Pour, ...American Journal of Hematology 96 (6), 708-718, 2021202
17
2021
Corneal changes after belantamab mafodotin in multiple myeloma patients
RB Bausell, A Soleimani, A Vinnett, MD Baroni, SA Staub, K Binion, ...Eye & Contact Lens 47 (6), 362-365, 2021202
16
2021
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
S Richard, A Chari, S Delimpasi, M Simonova, I Spicka, L Pour, I Kriachok, ...American Journal of Hematology 96 (9), 1120-1130, 2021202
15
2021
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
MV Mateos, M Gavriatopoulou, T Facon, HW Auner, X Leleu, R Hájek, ...Journal of Hematology & Oncology 14, 1-5, 2021202
13
2021
Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC …
S Lonial, R Popat, C Hulin, S Jagannath, A Oriol, PG Richardson, T Facon, ...Blood 138, 162, 2021202
11
2021
Clinical outcomes in patients (Pts) with dose reduction of selinexor in combination with bortezomib, and dexamethasone (XVd) in previously treated multiple myeloma from the …
S Jagannath, T Facon, AZ Badros, M Levy, P Moreau, S Delimpasi, ...Blood 138, 393, 2021202
7
2021
OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory …
S Lonial, PG Richardson, R Popat, EA Stadtmauer, JT Larsen, A Oriol, ...Clinical Lymphoma Myeloma and Leukemia 21, S9, 2021202
7
2021
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
R Sklavenitis-Pistofidis, MP Aranha, RA Redd, J Baginska, ...Cancer Cell 40 (11), 1358-1373. e8, 2022202
6
2022
Prospective observational study of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma: Microbiota profiling and cytokine expression
AZ Badros, M Meddeb, D Weikel, S Philip, T Milliron, R Lapidus, L Hester, ...Frontiers in Oncology 11, 704722, 2021202
6
2021
Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: Final analysis of the DREAMM-2 Trial
AK Nooka, A Cohen, HC Lee, AZ Badros, A Suvannasankha, N Callander, ...Blood 10 (Supplement 1), 7301-7303, 2022202
4
2022
Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple Myeloma-Results of the ascent trial
SK Kumar, M Alsina, B Laplant, AZ Badros, AO Abdallah, R Abonour, ...Blood 10 (Supplement 1), 1830-1832, 2022202
4
2022
Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?
R Popat, AZ Badros, S Kumar, P Rodríguez-Otero, AD Cohen, S Manier, ...Blood 18, 2746, 2021202
3
2021
P07: Results from the Cc-220-Mm-001 Dose-Expansion Phase of Iberdomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
NWCJ van de Donk, R Popat, C Hulin, S Jagannath, A Oriol, ...HemaSphere 6, 14-15, 2022202
3
2022

Referred From: https://scholar.google.ca/citations?user=1QyF7sQAAAAJ&hl=en

Cited by
Citations 17471
h-index 63
i10-index 162
Recommended Journals
Open Access Journals